Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: Results of the Yale mitomycin randomized trials

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 268-276

  Haffty, B G ^a   Son, Y H ^a   Papac, R ^a   Sasaki, C T ^a   Weissberg, J B ^a   Fischer, D ^a   Rockwell, S ^a   Sartorelli, A C ^a   Fischer, J J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICOUMAROL; MITOMYCIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; HEAD AND NECK CARCINOMA; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA;

EID: 0031032568     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.268     Document Type: Article

References (65)

1. Boring C, Squires T, Tong T, et al: Cancer statistics. CA Cancer J Clin 44:7-26, 1994
2. Kramer S, Gelber RD, Snow JB, et al: Combined radiation therapy and surgery in the management of advanced head and neck cancer: Final report of study 73-03 of the Radiation Therapy Oncology Group. Head Neck Surg 10:19-30, 1987
3. Parsons JT, Mendenhall WM, Million RR, et al: The management of primary cancers of the oropharynx: Combined treatment or irradiation alone? Semin Radiat Oncol 2:142-148, 1992
4. Vikram B, Strong EW, Shah J, et al: Elective postoperative radiation therapy in stages III and IV epidermoid carcinoma of the head and neck. Am J Surg 140:580-584, 1980
5. Million RR, Cassisi NJ (eds): Management of Head and Neck Cancer. A Multidisciplinary Approach. Philadelphia, PA, Lippincott, 1984, pp 43-96
6. Pajak TF, Laramore GE, Marcial VA, et al: Elapsed treatment days - A critical item for radiotherapy quality control review in head and neck trials: RTOG report. Int J Radiat Oncol Biol Phys 20:13-20, 1991
7. Pinto LHJ, Canary PCV, Araujo CMM, et al: Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 21:557-562, 1991
8. Schuller DE, Stein DW, Metch B: Analysis of treatment failure patterns. Arch Otolaryngol Head Neck Surg 115:834-836, 1989
9. Spiro JD, Spiro RH: Carcinoma of the tonsillar fossa. An update. Arch Otolaryngol Head Neck Surg 115:1186-1189, 1989
10. Tupchong L, Phil D, Scott CB, et al: Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: Long-term follow-up of RTOG study 73-03. Int J Radiat Oncol Biol Phys 20:21-28, 1991
11. Leibel SA, Scott CB, Mohiuddin M, et al: The effect of local-regional control on distant metastatic dissemination in carcinoma of the head and neck: Results of an analysis from the RTOG head and neck database. Int J Radiat Oncol Biol Phys 21:549-556, 1991
12. Merino QR, Lindberg RD, Fletcher GH: An analysis of distant metastasis from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 40:145-151, 1977
13. Kramer S, Marcial V, Pajak T, et al: Prognostic factors for loco-regional control and metastasis and the impact on survival. Int J Radiat Oncol Biol Phys 12:573-578, 1986
14. Rockwell S: Use of hypoxia-directed drugs in the therapy of solid tumors. Semin Oncol 19:29-40, 1992
15. Chapman JD: Measurement of tumor hypoxia by invasive and non-invasive procedures: A review of recent clinical studies. Radiother Oncol 20:13-19, 1991
16. Sartorelli AC: Therapeutic attack of hypoxic cells of solid tumors: Presidential address. Cancer Res 48:775-778, 1988
17. Gatenby RA, Kessler HB, Rosenblum JS, et al: Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14:831-838, 1988
18. Rockwell S, Moulder JE: Hypoxic fractions of human tumors xenografted into mice: A review. Int J Radiat Oncol Biol Phys 19:197-202, 1990
19. Moore JN, Hasleton PS, Buckley CH: Tumour cords in 52 human bronchial and cervical carcinomas: Inferences for their cellular kinetics and radiobiology. Br J Cancer 51:407-413, 1985
20. Griffin T, Davis R, Laramore G, et al: Fast neutron irradiation of metastatic cervical adenopathy. The results of a randomized RTOG study. Int J Radiat Oncol Biol Phys 9:1267-1270, 1983
21. Henk JM: Late results of a trial of hyperbaric oxygen and radiotherapy in head and neck cancer: A rationale for hypoxic cell sensitizer? Int J Radiat Oncol Biol Phys 12:1299-1341, 1986
22. Lee D-J, Cosmatos D, Marcial VA, et al: Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 32:567-576, 1995
23. Overgaard J: Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Radiat Oncol Res 6:509-518, 1994
24. Wasserman TH, Lee DJ, Cosmatos D, et al: Clinical trials with etanidazole (SR 2508) by the radiation therapy oncology group (RTOG). Radiother Oncol 22:129-135, 1991 (suppl 20)
25. Fischer JJ, Rockwell S, Martin DF: Perfluorochemicals and hyperbaric oxygen in radiation therapy. Int J Radiat Oncol Biol Phys 12:95-102, 1986
26. Sartorelli AC, Hodnick WF, Belcourt MF, et al: Mitomycin C: A prototype bioreductive agent. Oncology Res 501-508, 1994
27. Kennedy KA, Rockwell S, Sartorelli AC: Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Res 40:2356-2360, 1980
28. Rockwell S, Sartorelli A: Mitomycin C and radiation, in Hill BT, Bellamy A (eds): Antitumor Drug-Radiation Interactions. Boca Raton, FL, CRC Press, 1990, pp 125-139
29. Weissberg JB, Son YH, Papac RJ, et al: Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys 17:3-9, 1989
30. Haffty BG, Son YS, Sasaki CT, et al: Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: Results from two randomized clinical trials. Int J Radiat Oncol Biol Phys 27:241-250, 1993
31. Keyes SR, Rockwell S, Sartorelli AC: Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro. Cancer Res 45:5638-5643, 1984
32. Rockwell S, Keyes SR, Sartorelli AC: Modulation of the antineoplastic efficacy of mitomycin C by dicoumarol in vivo. Cancer Chemother Pharmacol 24:349-353, 1989
33. Haffty B, Papac R, Son Y, et al: Mitomycin C (MC) with dicoumarol (D) as an adjuvant to radiation therapy (RT) in squamous cell carcinoma (SCC) of the head and neck: Results of a randomized clinical trial. Proc Am Soc Clin Oncol 14:304, 1995 (abstr)
34. American Joint Committee on Cancer: Manual for Staging of Cancer (ed 4). Philadelphia, PA, Lippincott, 1992, pp 149-154
35. Efron B: Forcing a sequential experiment to be balanced. Biometrika 58:403-417, 1985
36. Perez C, Brady L: RTOG/radiation morbidity scoring criteria, in Perez C, Brady L (eds): Principles and Practice of Radiation Oncology. Philadelphia, PA, Lippincott, 1992, pp 51-55
37. PRODAS Database Analysis System Reference Manual. Houston, TX, Conceptual Software, 1985
38. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-486, 1958
39. Cox DR: Regression models and life tables. J R Stat Soc B34:187-220, 1972
40. Suit HD: The scope of the problem of primary tumor control. Cancer 61:2141-2147, 1988
41. Fu KK, Phillips TL, Silverberg IJ, et al: Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: Update of a Northern California Oncology Group Randomized Trial. J Clin Oncol 5:1410-1418, 1987
42. Head and Neck Contracts Program: Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the Head and Neck Contracts Program. Cancer 60:301-311, 1987
43. Holoye PV, Grossman TW, Toohill RJ, et al: Randomized study of adjuvant chemotherapy for head and neck cancer. Otolaryngol Head Neck Surg 93:712-719, 1985
44. Jacobs C, Makuch R: Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: A subset analysis of the Head and Neck Contracts Program. J Clin Oncol 8:838-847, 1990
45. Johnson JT, Myers EN, Schramm VL Jr, et al: Adjuvant chemotherapy for high-risk squamous-cell carcinoma of the head and neck. J Clin Oncol 5:456-458, 1987
46. Kun LE, Toohill RJ, Holoye PY, et al: Randomized study of adjuvant chemotherapy for cancer of the upper aerodigestive tract. Int J Radiat Oncol Biol Phys 12:173-178, 1986
47. Laramore GE, Scott CB, Al-Sarraf M, et al: Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys 23:705-713, 1992
48. Horiot JC, LeFur R, N'Guyen T: Hyperfractionated vs conventional fractionation in oropharyngeal carcinoma: Final analysis. A randomized trial of the EORTC Cooperative Group of Radiotherapy. Radiother Oncol 25:231-241, 1992
49. Rentschler RE, Wilbur DW, Petti GH, et al: Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas - A prospective, randomized study. J Clin Oncol 5:278-285, 1987
50. Schuller DE, Metch B, Stein DW, et al: Preoperative chemotherapy in advanced resectable head and neck cancer: Final report of the Southwest Oncology Group. Laryngoscope 98:1205-1211, 1988
51. Taylor SG IV, Applebaum E, Showel JL, et al: A randomized trial of adjuvant chemotherapy in head and neck cancer. J Clin Oncol 3:672-679, 1985
52. Wang CC: Local control of oropharyngeal carcinoma after two accelerated hyperfractionation radiation therapy schemes. Int J Radiat Oncol Biol Phys 14:1143-1146, 1988
53. Merlano M, Vitale V, Rosso R, et al: Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. New Engl J Med 327:1115-1121, 1992
54. Smid L, Lesnicar H, Zakotnik B, et al: Radiotherapy, combined with simultaneous chemotherapy with mitomycin C and bleomycin for inoperable head and neck cancer - Preliminary report. Int J Radiat Oncol Biol Phys 32:769-775, 1995
55. Jacobs C: Adjuvant and neoadjuvant treatment of head and neck cancers (review). Semin Oncol 18:504-514, 1991
56. Taylor SG: Why has so much chemotherapy done so little in head and neck cancer? J Clin Oncol 5:1-3, 1987 (editorial)
57. Eschwege F, Sancho-Garnier H, Gerard JP: Ten-year results of randomized trial comparing radiotherapy and concomitant bleomycin to radiotherapy alone in epidermoid carcinoma of the oropharynx: Experience of the European Organization for Research and Treatment of Cancer. Natl Cancer Inst Monogr 6:275-278, 1988
58. Cummings BJ, Keane TJ, O'Sullivan B, et al: Epidermoid anal cancer: Treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys 21:1115-1125, 1991
59. Coia LW, Engstrom PF, Paul AR, et al: Long-term results of infusional 5-FU, mitomycin-C, and radiation as primary management of esophageal carcinoma. Int J Radiat Oncol Biol Phys 20:29-36, 1991
60. Sivanesaratnam V, Jayalakshmi P: Mitomycin C adjuvant chemotherapy after Wertheim's hysterectomy for stage IB cervical cancer. Cancer 64:798-800, 1989
61. Dobrowsky W: Unconventional fractionation with or without mitomycin C in advanced head and neck cancer. Semin Oncol 2:45-47, 1992
62. Dobrowsky W, Dobrowsky E, Strassl H, et al: Response to preoperative concomitant radiochemotherapy with mitomycin C and 5-fluorouracil in advanced head and neck cancer. Eur J Cancer Clin Oncol 25:845-849, 1989
63. Keyes SR, Rockwell S, Sartorelli AC: Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic tumor cells in vivo and in vitro. Cancer Res 45:3642-3645, 1985
64. Rockwell S, Keyes SR, Sartorelli AC: Preclinical studies of porfiromycin as an adjunct to radiotherapy. Radiat Res 116:100-113, 1988
65. Haffty BG, Son YH, Moini M, et al: Porfiromycin as an adjunct to radiation therapy in squamous cell carcinoma of the head and neck: Results of phase I clinical trial. Radiat Oncol Invest 1:297-304, 1994